Home/Publication/Qiming & K2VC Double Down on Immunotherapy
Qiming & K2VC Double Down on Immunotherapy 

02 Jun 2023

US$ 19.00

Qiming Venture Partners (Qiming) has led and made a follow-on investment in the pre-series A plus funding round of LTZ T...

Price / article: US$19.00
OR existing subscriber
Related Publications

International Finance Corp has committed up to US$50 m to Emerging Asia Infrastructure Credit Fund, managed by ......

Subscribers’ Weekly ending 22 May 2026...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.